Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma by unknown
CASE REPORT Open Access
Comparative genetic analysis of a rare
synchronous collision tumor composed of
malignant pleural mesothelioma and
primary pulmonary adenocarcinoma
Tomoaki Naka1, Yutaka Hatanaka1,2, Katsuji Marukawa1, Hiromi Okada1, Kanako C. Hatanaka1,
Jun Sakakibara-Konishi3, Satoshi Oizumi3, Yasuhiro Hida4, Kichizo Kaga4, Tomoko Mitsuhashi1
and Yoshihiro Matsuno1,2*
Abstract
Background: Although asbestos acts as a potent carcinogen in pleural mesothelial and pulmonary epithelial cells,
it still remains unclear whether asbestos causes specific and characteristic gene alterations in these different kinds
of target cells, because direct comparison in an identical patient is not feasible. We experienced a rare synchronous
collision tumor composed of malignant pleural mesothelioma (MPM) and primary pulmonary adenocarcinoma
(PAC) in a 77-year-old man with a history of long-term smoking and asbestos exposure, and compared the DNA
copy number alteration (CNA) and somatic mutation in these two independent tumors.
Methods: Formalin-fixed paraffin-embedded (FFPE) tissues of MPM and PAC lesions from the surgically resected
specimen were used. Each of these MPM and PAC lesions exhibited a typical histology and immunophenotype.
CNA analysis using SNP array was performed using the Illumina Human Omni Express-12_FFPE (Illumina, San Diego,
CA, USA) with DNA extracts from each lesion. Somatic mutation analysis using next-generation sequencing was
performed using the TruSeq Amplicon Cancer Panel (Illumina).
Results: The CNA analysis demonstrated a marked difference in the frequency of gain and loss between MPM and
PAC. In PAC, copy number (CN) gain was detected more frequently and widely than CN loss, whereas in MPM there
was no such obvious difference. PAC did not harbor CNAs that have been identified in asbestos-associated lung
cancer, but did harbor some of the CNAs associated with smoking. MPM exhibited CN loss at 9p21.2-3, which is the
most common genetic alteration in mesothelioma.
Conclusion: In this particular case, asbestos exposure may not have played a primary role in PAC carcinogenesis,
but cigarette smoking may have contributed more to the occurrence of CN gains in PAC. This comparative genetic
analysis of two different lesions with same amount of asbestos exposure and cigarette smoke exposure has
provided information on differences in the cancer genome related to carcinogenesis.
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Background
Asbestos is well known to be a causative agent both of
malignant mesothelioma and lung cancer. It has been re-
ported that asbestos causes genetic alterations at the
chromosomal level [1]. Loss at 9p21 and DNA copy
number alteration (CNA) have been identified in meso-
thelioma [2–6], whereas allelic imbalance at 2p16,
9q33.1 and 19p13 has been reported in asbestos-
associated lung cancer [7]. Although asbestos is consid-
ered to act as a potent carcinogen both in pleural meso-
thelial cells and pulmonary epithelial cells, several
studies have suggested that there seems to be less analo-
gous abnormality observed between neoplasms derived
from each of them [8]. However, it still remains unclear
whether asbestos causes specific and characteristic gene
alterations in these different kinds of target cells, be-
cause simultaneous occurrence of these neoplasms after
asbestos exposure in an identical patient is exceedingly
rare [9, 10], and thus direct comparison of the respective
gene alterations is not feasible. We encountered a pa-
tient with a history of both long-term smoking and
asbestos exposure who underwent extrapleural pneu-
monectomy and was proved to have a synchronous
collision tumor consisting of malignant pleural meso-
thelioma (MPM) and primary pulmonary adenocarcin-
oma (PAC). It was expected that comprehensive genetic
analysis of these two different tumors with a possible rela-
tionship to asbestos exposure and cigarette smoke expos-
ure would aid understanding of thoracic carcinogenesis.
In the present study, therefore, we compared CNA and
somatic mutation in this case synchronous collision tumor
consisting of MPM and PAC.
Case presentation
Clinical summary
A 77-year-old Japanese man with a 20-pack-year history
of cigarette smoking also had a history of asbestos expos-
ure while working in the construction industry between
the ages of 40 and 65. He was admitted to our hospital
complaining of coughing, sputum and breathlessness,
which had developed gradually. A chest X-ray of his left
lung demonstrated an abnormal shadow, and chest com-
puted tomography (CT) revealed left pleural effusion, dif-
fuse pleural thickening and infiltrates with cavitations in
the left lung. The levels of all serum tumor markers exam-
ined, including carcinoembryonic antigen (CEA), carbohy-
drate antigen 19-9 (CA19-9), squamous cell carcinoma
antigen (SCC), neuron-specific enolase (NSE), cytokeratin
fragment (CYFRA), and pro-gastrin-releasing peptide
(Pro-GRP), were within the normal ranges. Cytological
examination of the left pleural effusion detected malignant
mesothelial cells, and a preoperative clinical diagnosis of
MPM was made. Chest and abdominal CT imaging
demonstrated no detectable distant metastasis. Left extra-
pleural pneumonectomy was performed.
Pathologic findings
Cross-sectional examination of the resected specimen
showed that the left lung was widely covered by diffuse
pleural thickening confluent with the multinodular
grayish-white solid tumor (Fig. 1). The tumor involved
both the parietal and visceral pleurae, invading the dia-
phragm and mediastinal tissues surrounding the thoracic
aorta. In the close vicinity of this major pleural tumor
described above, an intrapulmonary tumor was found in
the lower lobe (Fig. 1). This latter tumor had an ill-
defined border and a gray-white cut surface. This intra-
pulmonary tumor had not been demonstrated in the
preoperative imaging work-up.
Histologically, these two tumors showed distinct
features. The pleural tumor was composed of neo-
plastic cells growing in a tubulopapillary pattern, or
in solid sheets or nests in some areas (Fig. 2a). Most
of the papillae were covered by a single layer of cu-
boidal tumor cells, and the pseudoglands were lined
by similar cells, often with a solid growth pattern.
These histologic findings were conclusive of MPM,
epithelioid type. On the other hand, the intrapulmon-
ary tumor was composed of neoplastic cells showing
lepidic growth in the peripheral portion, and papillary
or acinar invasive growth patterns in the central por-
tion (Fig. 2b). Its stroma varied from fibrous to des-
moplastic. These findings suggested a diagnosis of
PAC, which is invasive adenocarcinoma, lepidic pre-
dominant (lepidic 60 %, papillary 30 %, acinar 10 %)
according to Sica’s classification [11]. The two tumors,
MPM and PAC, collided within the same lower lobe
of the left lung (Fig. 2c, d). Asbestos bodies were
detected rather easily in HE-stained sections of the sub-
pleural or peribronchial non-tumorous lung parenchyma.
Fig. 1 Macroscopic appearance of the synchronous collision tumor.
A cross-section of the resected specimen shows diffuse pleural
thickening confluent with the multinodular grayish-white solid
tumor (red arrow), and an intrapulmonary tumor showing an
irregular and ill-defined border and a gray-white cut surface (blue
arrow) colliding within the left lower lobe of the lung
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Immunohistochemistry (IHC) showed that the cells in
the pleural tumor were positive for calretinin and D2-40,
but negative for TTF-1 and Ber-EP4 (Fig. 2e, f ), being
consistent with the diagnosis of epithelioid-type MPM.
In contrast, the cells in the intrapulmonary tumor were
positive for TTF-1 and Ber-EP4, but negative for calreti-
nin and D2-40 (Fig. 2e, f ), thus confirming that the latter
tumor was PAC.
The results of our various examinations allowed us to
make a final diagnosis of collision tumor consisting of
two lesions: epithelioid-type MPM, and PAC. Molecular
testing performed on the PAC showed negativity for
EGFR, KRAS/NRAS/BRAF gene mutations and ALK fu-
sion protein.
Methods
DNA extraction from formalin-fixed paraffin-embedded
(FFPE) tissues
FFPE tissues of MPM and PAC were manual macrodis-
sected and DNA was extracted with a QIAamp DNA FFPE
Tissue Kit (Qiagen). The quantity of the purified DNA
sample was analyzed with a PicoGreen dsDNA Quantita-
tion Kit (Life Technologies, Carlsbad, CA, USA). The total
DNA yield was >1000 ng for both MPM and PAC. The
quality of the DNA sample was then assessed using a quan-
titative PCR assay with the Infinium HD FFPE QC kit (Illu-
mina, San Diego, CA, USA) to determine if the DNA
sample obtained was applicable to genetic analyses.
CNA analysis using SNP array
After passing the DNA quality assessment, the sample
with amplifiable DNA from FFPE tissues was then re-
stored using the Infinium HD FFPE Restore Kit (Illu-
mina) in accordance with the manufacturer’s
instructions. The restored DNA sample was fluores-
cently labeled with cyanine dye Cy5, and control DNA
was labeled with cyanine dye Cy3 in accordance with the
manufacturer’s instructions. Labeled products were
cohybridized to the Illumina Human Omni Express-
12_FFPE (Illumina). Microarray data were analyzed
using Genome Studio software (Illumina).
Fig. 2 Histology and immunohistochemistry of the two lesions of the synchronous collision tumor. Representative histologic features of the
diffuse pleural thickening (a), epithelioid-type MPM, and the intrapulmonary tumor (b), PAC. c and d show the area of collision, PAC being
distributed on the upper left, and MPM on the lower right. d Is the magnified images of the rectangle area in (c). MPM and PAC exhibit typical
immunohistochemical staining for TTF-1 (e) and calretinin (f), respectively
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Somatic mutation analysis using next-generation
sequencing
Target sequencing was performed on the MiSeq plat-
form using a TruSeq Amplicon Cancer Panel, which is a
highly multiplexed next-generation sequencing (NGS)
system covering 212 regions in 48 cancer-related genes
(Illumina), and then the NGS data were analyzed using
the MiSeq Reporter software [12].
Results
Genetic alteration in the MPM lesion
In the MPM lesion, copy number (CN) gain was de-
tected widely throughout almost the whole of chromo-
some 8 (Fig. 3). In addition, CN loss was detected in
several limited regions in the long arm of chromosome 6
and at 9p21.2-3, both of which are the common genetic
alterations in mesothelioma [2–6, 13]. Other short-
region gains were found at 3q22-23, 9q34.2, 17q22-25,
and 22q13.3, and losses were found at 1p31.2-1p12.1,
3p24.3, 4q21.13-22.1, 13q21.31, 13q33.3, and 15q22.2.
Copy-neutral loss of heterozygosity (LOH) was found at
1p31.1, 2p16.2-16.1, 3p12.1, 5q14.3, 5p15.2, and 15q23-
24.1. Gene alterations at 22q12.2 and 17p13.1 were not
detected. Somatic mutation was observed in ATM
(G2706A). Possible germline mutations of TP53 (P72R)
and KDR (Q472H) were also observed in both MPM
and PAC lesions with mutation rates of almost 50 %
(data not shown).
Genetic alteration in the PAC lesion
In the PAC lesion, CN gain occurred more frequently
than loss (Fig. 3), and was found throughout almost the
whole of the chromosomes 3, 10, 12, 17, 18, and 19, on
the long arm of chromosomes 13, 14, 15, and 22, and on
the short arm of chromosome 9. Other region gains
were found at 1p36, 2p23-14,5p15.2, 5q21, 6q21-22.1,
8q24. Loss and copy-neutral LOH were rarely found.
There were no detectable alterations at 2p16, 9q33.1 or
19p13, which have been reported previously in asbestos-
associated lung cancer [7]. PAC had somatic mutation of
ERBB4 (300 fs, 301 fs) and STK11 (E65G), as well as
TP53 (P72R) and KDR (Q472H) with the possibility of
the germline mutations.
Comparison of CNA between the MPM and PAC lesions
Our CNA analysis revealed that the frequency of gain
and loss differed between MPM and PAC. In PAC, CN
gain was frequently and widely detected in comparison
with CN loss, whereas in MPM there was no such ten-
dency for marked gain/loss imbalance, and large-region
CNA was detected only on limited chromosomes, in-
cluding chromosome 8 with CN gains. When we focused
on individual chromosomes, CNAs were found in almost
all regions of the 6q arm in both of the tumor lesions.
No CNA was found on chromosome 16 or 21 in either
MPM or PAC. Gains or losses on chromosomes 4, 7 and
11 were found only in MPM, and on chromosomes 14,
19 and 20 only in PAC.
Discussion
Recent improvements in molecular-based technologies
have enabled the use of routine FFPE tissue materials for
highly informative genetic analyses. In the present study
using these FFPE-related technologies, we attempted to
analyze CNA and somatic mutation in a collision tumor
consisting of MPM and PAC. Coexistence of MPM and
PAC is extremely rare, although both may be caused by
asbestos exposure. Only a few such cases have been re-
ported previously, as judged from citations confirmable
on the PubMed database [9, 10], and therefore we con-
sider that this is the first reported study to have compre-
hensively compared CNA and somatic mutation in the
MPM and PAC lesions of a collision tumor. We consider
that comparative analysis of independent tumors occur-
ring in a single patient would provide useful information
on direct differences in the cancer genome without any
biological variations in the tumor or the need to con-
sider research cohort sizes.
In the present case, loss of 9p21.2-3 was detected in
the MPM lesion. Deletion of 9p21, encoding the CDK
inhibitors, p16INK4a, p14ARF and p15INK4b, has been ob-
served in up to 80 % of mesotheliomas [2–6]. Thus, in
addition to the typical morphologic features, the MPM
lesion of the present collision tumor harbored the gene
alterations typical of malignant mesothelioma. Allelic
loss of NF2, located at 22q12.2, has been reported in up
to 70 % of mesotheliomas [2, 14, 15]. Loss of
1 2 3 4 5 6 7 8 9 10 11 12 13
14 15 1716 18 19 20 2221
Fig. 3 Karyotype of the synchronous collision tumor comparing
MPM and PAC. Lines to the left of the chromosomes represent MPM
and lines to the right represent PAC. Orange lines represent losses,
green lines represent gains, and gray lines represent copy-neutral
loss of heterozygosity (LOH). Loss of 9p21, which is the common
genetic alterations in mesothelioma, was found in the MPM lesion
(orange arrow)
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chromosome 17p13.1, encoding the p53 gene TP53, is
also a common and important change in mesothelioma
[2]. Gene alterations at 22q12.2 and 17p13.1 were not
detected in the present case.
On the other hand, loss at 2p16 and 19p13, and gain
and loss at 9q33.1 were recently identified in asbestos-
associated lung cancer and considered to be associated
with the genotoxic effect of asbestos [7]. The region en-
coding p16INK4a has also been shown to have a higher
incidence of LOH and homozygous deletion in asbestos-
associated lung cancer [16]. In the present case, however,
no alterations in these major regions were found in the
PAC lesion. Conversely, CNA occurred widely in almost
all chromosome regions and was more frequent than in
the MPM lesion. These results suggest that asbestos ex-
posure may not have played a primary role in PAC car-
cinogenesis in this particular case, and that factors other
than asbestos may have been involved.
As mentioned above, this patient also had a 20-pack-
year history of cigarette smoking in addition to asbestos
exposure. As CNAs associated with smoking, 12q23,
3q24, 8q24, 5q, 8q, 16p, 19p, 22q, 15q25, 8p11.23-8p12,
and 17p13.1 have been reported [17–21], and some of
them were found in the PAC lesion in the present case.
However, no definite genetic alteration specific for
smoking was found [17]. An investigation of LOH and
TP53 mutation by Inamura et al. has revealed combined
effects of asbestos and cigarette smoking in the develop-
ment of lung adenocarcinoma [22]. Moreover, Nymark
et al. have reported that such a combination may lead to
an increase in CNA, thus increasing the risk of cancer
[7]. Taken together, these data suggest that, in the
present case, cigarette smoking may have contributed
more to the occurrence of CN gains in the PAC lesion
than asbestos exposure.
One of the aims of this case study was to obtain data
to indicate whether asbestos and cigarette smoking
causes specific and characteristic gene alterations in
these different kinds of target cells. Even in this single
patient, the genetic events occurring in the two colliding
tumors were quite different. This implies that tumor
types arising from different cells, with same amount of
asbestos exposure and cigarette smoke exposure and
both in the thorax, would be differently impacted by
each type of carcinogen exposure, though no conclusive
evidence would be possible from this case study alone. A
comprehensive genetic analysis of archival FFPE tissues
would provide promising information to clarify this
issue.
Conclusion
We have compared CNA and somatic mutation in an
exceedingly rare synchronous collision tumor consisting
of MPM and PAC. Our CNA analysis showed that the
frequencies of gain and loss were quite different between
MPM and PAC. A comprehensive genetic analysis of
these two different tumor types would provide data
helpful for better understanding the thoracic carcinogen-
esis resulting from asbestos and cigarette smoking
exposure.
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